STOCK TITAN

Mainz Biomed NV Stock Price, News & Analysis

MYNZ Nasdaq

Welcome to our dedicated page for Mainz Biomed NV news (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed NV stock.

Mainz Biomed NV (MYNZ) pioneers non-invasive cancer detection through advanced molecular diagnostics like its flagship ColoAlert test. This page aggregates official news releases and clinical updates critical for understanding the company’s progress in colorectal and pancreatic cancer screening.

Investors and researchers will find timely updates on regulatory milestones, product developments, and strategic partnerships. Content spans clinical trial results, technology enhancements leveraging AI, and market expansion efforts across Europe and North America.

Key focus areas include advancements in PCR-based testing, collaborations with medical institutions, and data from ongoing studies. Bookmark this page to efficiently track Mainz Biomed’s contributions to early cancer detection and molecular diagnostics innovation.

Rhea-AI Summary

Mainz Biomed (NASDAQ:MYNZ) has announced a strategic partnership with labor team w ag to launch ColoAlert®, a DNA-based colorectal cancer (CRC) screening test, in Switzerland. This marks Mainz Biomed's first entry into the Swiss market, where thousands of new CRC cases are diagnosed annually.

The partnership combines Mainz Biomed's DNA-based diagnostic expertise with labor team w's established laboratory services network. The ColoAlert® test will be available through labor team w's healthcare provider network starting in spring 2025, offering Swiss patients access to advanced CRC screening technology.

This collaboration aims to increase CRC screening participation rates and improve early detection capabilities in Switzerland. The partnership represents an expansion of Mainz Biomed's European market presence with its flagship product ColoAlert®, which is the first DNA-based CRC screening test in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.28%
Tags
none
-
Rhea-AI Summary

Mainz Biomed (NASDAQ:MYNZ) and GANZIMMUN Diagnostics have launched an enhanced version of the ColoAlert colorectal cancer screening test across Germany, timing the release with March's Colorectal Cancer Awareness Month. The improved test, first introduced in mid-2024, features a proprietary DNA stabilizing buffer that ensures accurate results regardless of sample volume variations.

The launch coincides with Germany's updated national screening guidelines, which now provide equal access to colorectal cancer screening for both men and women starting at age 50, eliminating previous gender-based differences. This change follows research by the Institute for Quality and Efficiency in Health Care (IQWiG) that found no significant gender-based variations in recommended screening methods.

According to Tarrin Khairi-Taraki, VP Commercial Operations at Mainz Biomed, this development advances their mission of improving colorectal cancer prevention and detection. The collaborative effort between Mainz Biomed and GANZIMMUN demonstrates their commitment to enhancing cancer diagnostics through innovative solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.28%
Tags
none
-
Rhea-AI Summary

Mainz Biomed (NASDAQ:MYNZ) has successfully regained full compliance with Nasdaq Capital Market listing requirements. The company received formal notice from Nasdaq on January 23, 2025, confirming its compliance with the minimum stockholders' equity requirement under Listing Rule 5550(b)(1). This follows their previous confirmation of compliance with the minimum bid price requirement under Rule 5550(a)(2). As a result, MYNZ will maintain its listing and continue trading on the Nasdaq Capital Market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.79%
Tags
none
Rhea-AI Summary

Mainz Biomed (NASDAQ:MYNZ) has launched eAArly DETECT 2, a U.S. feasibility study to evaluate its next-generation colorectal cancer (CRC) test. The study will assess the performance of the company's proprietary mRNA biomarkers, AI-developed algorithm, and FIT test across approximately 2,000 average-risk patients.

The study aims to validate previous promising results and is expected to complete enrollment in the second half of 2025, with topline results targeted for Q4 2025. Following this study, Mainz Biomed plans to finalize protocols for ReconAAsense, their U.S. pivotal study scheduled for 2026.

The next-generation test incorporates five novel gene expression biomarkers acquired from Sherbrooke University in 2022, designed to detect both advanced adenomas (precancerous polyps) and early-stage CRC with high accuracy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
-
Rhea-AI Summary

Mainz Biomed (NASDAQ:MYNZ) has partnered with Quest Diagnostics to advance its colorectal cancer screening test. Quest will provide laboratory services for Mainz's ReconAAsense FDA study, which will involve approximately 15,000 subjects across 150 US sites. The agreement includes an option for Quest to obtain semi-exclusive rights for testing services pending FDA approval.

The company's ColoAlert test, utilizing PCR technology to analyze stool samples for cancer DNA, has demonstrated promising sensitivity in detecting colorectal cancer and advanced adenomas. This development targets a significant market opportunity, as about one-third of US residents aged 50-75 have never undergone colorectal cancer screening, representing a potential $4.0B+ market in the US.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.19%
Tags
-
Rhea-AI Summary

Mainz Biomed (NASDAQ:MYNZ) has completed its previously announced follow-on offering, raising $8.0 million in gross proceeds. The offering consisted of 1,367,521 units priced at $5.85 per unit. Each unit includes one ordinary share (or prefunded warrant), one Class A warrant, and one Class B warrant to purchase ordinary shares.

The Class A warrants are exercisable at $5.85 per share with a five-year expiration, while Class B warrants, also exercisable at $5.85, will expire either 30 days after the eAArly Detect 2 study results or one year from issuance. Maxim Group served as the sole placement agent for this at-the-market offering under Nasdaq rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
none
Rhea-AI Summary

Mainz Biomed (NASDAQ:MYNZ) has announced the pricing of a follow-on offering expected to raise $8.0 million in gross proceeds. The offering consists of 1,367,521 units, each priced at $5.85 and including one ordinary share (or prefunded warrant), one Series A warrant, and one Series B warrant.

The Series A warrants will be exercisable at $5.85 per share with a five-year expiration, while Series B warrants, also exercisable at $5.85, will expire either 30 days after the eAArly Detect 2 study results or one year from issuance. Maxim Group is serving as the sole placement agent, with the offering expected to close around December 16, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
none
-
News
Rhea-AI Summary

Mainz Biomed (NASDAQ:MYNZ) announced a 1-for-40 reverse stock split effective December 3, 2024. The split will reduce outstanding shares from approximately 80.1 million to 2.0 million. This action aims to increase market price per share to comply with Nasdaq's continued listing requirements. The company received notice of non-compliance with Nasdaq's minimum bid price requirement of $1.00 and the $2,500,000 minimum stockholders' equity requirement. Following a staff determination letter, Mainz Biomed plans to request a hearing to stay any suspension or delisting action.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.06%
Tags
-
Rhea-AI Summary

Mainz Biomed (NASDAQ:MYNZ) has announced a collaborative agreement with Thermo Fisher Scientific to jointly develop and potentially commercialize Mainz's Next Generation colorectal cancer screening product. The collaboration will utilize Thermo Fisher's technologies, instrumentation, and information translation systems to develop proprietary mRNA-based screening tests.

The partnership aims to enhance Mainz Biomed's non-invasive test that targets both early detection of colorectal cancer and precancerous lesions, particularly advanced adenomas. The development will take place at Mainz Biomed's laboratories in Mainz, Germany, focusing on creating a home collection colorectal screening tool with enhanced adenoma detection capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.7%
Tags
none
Rhea-AI Summary

Mainz Biomed N.V. (NASDAQ:MYNZ) reported mid-year 2024 financial results and provided a corporate update. Key highlights include:

- Revenue increased 4% year-over-year
- Loss from operations decreased by 32%
- Presented groundbreaking results at DDW 2024 and ASCO 2024, showing high sensitivity for colorectal cancer (CRC) and advanced adenomas
- Improved ColoAlert® product with new DNA stabilizing buffer
- Expanded collaboration with Liquid Biosciences for pancreatic cancer detection
- Received FDA feedback on breakthrough device designation
- Announced strategic focus on three key initiatives for 2024-2025

The company aims to grow its ColoAlert® business in Europe, develop its next-generation CRC screening product, and conduct a 2,000-patient study (eAArly DETECT 2) in the U.S. Mainz Biomed also implemented cost reductions to streamline operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags

FAQ

What is the current stock price of Mainz Biomed NV (MYNZ)?

The current stock price of Mainz Biomed NV (MYNZ) is $1.43 as of July 3, 2025.

What is the market cap of Mainz Biomed NV (MYNZ)?

The market cap of Mainz Biomed NV (MYNZ) is approximately 5.3M.
Mainz Biomed NV

Nasdaq:MYNZ

MYNZ Rankings

MYNZ Stock Data

5.34M
3.74M
4.98%
11.06%
3.59%
Diagnostics & Research
Healthcare
Link
Germany
Mainz